CELC - セルクイティ― （Celcuity Inc.）

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its par…

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen''s 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023. Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, is scheduled to present at 11:10 a.m. ET on Wednesday, March 8, 2023. A live webcast of the presentation will be available using this weblink: https://wsw.com/webcast/cowen132/celc/1975134 . Alternatively, the live webcast will be accessible from the Investors section of the company''s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live event. About Celcuity Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company''s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor.

Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in prostate cancer cell lines. The poster was presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which is being held February 16-18, 2023. The presentation titled "Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status" demonstrated gedatolisib''s superior potency and efficacy across different prostate cancer cell lines relative to other PI3K/AKT/mTOR inhibitors of PTEN or PI3K status. "The findings further demonstrate gedatolisib''s differentiated mechanism of action and potential to treat various solid tumor types," said Brian Sullivan, Celcuity''s Chief Executive Officer and co-founder. "The results suggest that gedatolisib may help overcome or prevent development of resistance to androgen receptor inhibitors, which is particularly relevant in metastatic castration resistant prostate cancer (mCRPC)." This poster is available on the publications page of the Celcuity website.

NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celcuity Inc. (NASDAQ: CELC). If you are a…

MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proc…

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its par…

MINNEAPOLIS, MN / ACCESSWIRE / March 1, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced its participation in Cowen''s 43rd Annual Health Care Conference to be held in Boston on March 6-8, 2023. Brian Sullivan, Chief Executive Officer and co-founder of Celcuity, is scheduled to present at 11:10 a.m. ET on Wednesday, March 8, 2023. A live webcast of the presentation will be available using this weblink: https://wsw.com/webcast/cowen132/celc/1975134 . Alternatively, the live webcast will be accessible from the Investors section of the company''s website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after the live event. About Celcuity Celcuity is a clinical-stage biotechnology company focused on development of targeted therapies for treatment of multiple solid tumor indications. The company''s lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTOR inhibitor.

Gedatolisib demonstrated superior potency and efficacy in prostate cancer cell lines compared to other PI3K/AKT/mTOR inhibitors evaluated regardless of PI3K or PTEN status MINNEAPOLIS, MN / ACCESSWIRE / February 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today presented data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in prostate cancer cell lines. The poster was presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU), which is being held February 16-18, 2023. The presentation titled "Therapeutic effect of gedatolisib, a pan-PI3K/mTOR inhibitor, on prostate cancer models with PI3K or PTEN mutational status" demonstrated gedatolisib''s superior potency and efficacy across different prostate cancer cell lines relative to other PI3K/AKT/mTOR inhibitors of PTEN or PI3K status. "The findings further demonstrate gedatolisib''s differentiated mechanism of action and potential to treat various solid tumor types," said Brian Sullivan, Celcuity''s Chief Executive Officer and co-founder. "The results suggest that gedatolisib may help overcome or prevent development of resistance to androgen receptor inhibitors, which is particularly relevant in metastatic castration resistant prostate cancer (mCRPC)." This poster is available on the publications page of the Celcuity website.

NEW YORK, Dec. 20, 2022 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Celcuity Inc. (NASDAQ: CELC). If you are a…

MINNEAPOLIS, MN / ACCESSWIRE / December 12, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company, today announced the closing of its private placement, resulting in gross proc…

Seasoned executive brings over two decades of pharmaceutical business development and commercial strategy experience to Celcuity''s Board of DirectorsMINNEAPOLIS, MN / ACCESSWIRE / September 14, 2022 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage …

Celcuity Inc. (NASDAQ:NASDAQ:CELC) Q2 2022 Earnings Conference Call August 11, 2022 04:30 PM ET Company Participants Robert Uhl - Westwicke Partners, LLC Brian Sullivan - Co-Founder,…

The following slide deck was published by Celcuity Inc.

Celcuity (NASDAQ: CELC ) reported its Q2 earnings results on Thursday, August 11, 2022 at 04:00 PM. Here''s what investors need to know about the announcement. Earnings Celcuity missed estimated earnings by 10.0%, reporting an EPS … Full story available on Benzinga.com

Celcuity press release (CELC): Q2 GAAP EPS of -$0.55.At June 30, 2022, Celcuity had cash and cash equivalents of $66.9 million, compared to cash and cash equivalents of $84.3 million…